Andre Overesch
5 Papers
Andre Overesch is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy
Jakhongir F Alidjanov,Andre Overesch,Dimitri Abramov-Sommariva,Martina Hoeller,Hubert Steindl,Florian M.E. Wagenlehner,Kurt G. Naber +6 more
TL;DR: It is shown that the ACSS questionnaire, validated in several languages, has the potential to be used as a suitable instrument for diagnostics and patient-reported outcomes in well-designed, international, clinical studies investigating different treatment modalities of uncomplicated urinary tract infections.
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.
Yago Nieto,P. Banerjee,Indreshpal Kaur,Rafet Basar,Ye E. Li,May Daher,Hind Rafei,Lucila Nassif Kerbauy,Mecit Kaplan,David Marin,Lori Griffin,Melissa Barnett,R. Bassett,Nadima Uprety,R. Shrestha,Francia Reyes Silva,S. Islam,Christina Ganesh,Zephanie Borneo,Jeremy Ramdial,Chitra Hosing,Amin M. Alousi,Uday R. Popat,Muzaffar H. Qazilbash,Swaminathan P. Iyer,Tania P Sainz,F. Vega,Natalie Wall Fowlkes,Karenza Alexis,Michael F. Pittsburgh Emig,Andreas Harstrick,Andre Overesch,Elizabeth J. Shpall,Katayoun Rezvani +33 more
8
Afm13 in patients with cd30 positive relapsed or refractory (r/r) peripheral t cell lymphoma (ptcl): results from the phase 2 redirect study
W.S. Kim,Jake Shortt,Pier Luigi Zinzani,N. Mikhaylova,Ana Marin-Niebla,Dejan Radeski,Vincent Ribrag,Eva Domingo Domenech,Ahmed Sawas,Konan Alexis,Michael Emig,Linta Garcia,Andre Overesch,K. Pietzko,Steven M. Horwitz +14 more
TL;DR: Kim et al. as discussed by the authors evaluated the efficacy of AFM13 in patients with select R/R PTCL subtypes, exhibiting histologically confirmed CD30+expression in ≥ 1% tumor cells, who had received ≥ 1 prior systemic therapy.
AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)
Alison J. Moskowitz,Andreas Harstrick,Michael F. Pittsburgh Emig,Andre Overesch,Sheena Pinto,Paulien Ravenstijn,Thomas Schlüter,Jennifer Rubel,Hans Rebscher,Thorsten Graefe,John Lim,Heather Raymon,Karenza Alexis +12 more
TL;DR: A Phase 2 study is designed to evaluate the efficacy and safety of AFM13 in combination with AB-101 in patients with R/R HL and certain R/R CD30 + PTCL subtypes.
Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)
Won Seog Kim,Jake Shortt,P. L. Zinzani,Natalya Mikhaylova,Ana Marin-Niebla,Dejan Radeski,Vincent Ribrag,Eva Domingo Domenech,Ahmed Sawas,Karenza Alexis,Michael Emig,Andre Overesch,K. Pietzko,Steven M. Horwitz +13 more
TL;DR: AFM13 as discussed by the authors is a tetravalent, bispecific Innate Cell Engager (ICE ® ) that binds CD30 when expressed on PTCL cells, and CD16A on innate effector cells, redirecting and enhancing the innate immune response to CD30+ tumor cells.